

## HRP Goat anti-mouse IgG (minimal x-reactivity) Antibody

<b>Catalog# / Size</b>	405306 / 500 µL
<b>Clone</b>	Poly4053
<b>Regulatory Status</b>	RUO
<b>Isotype</b>	Goat Polyclonal IgG
<b>Description</b>	This polyclonal goat anti-mouse IgG antibody reacts with the heavy chains of mouse IgG and with the light (kappa and lambda) chains common to most mouse immunoglobulins. No cross-reactivity has been detected against non-immunoglobulin serum proteins. This antibody has been solid-phase absorbed to ensure minimal cross-reaction with rat, human, bovine, horse, and rabbit immunoglobulins, but it may have minimal cross-reactivity with other subclasses of mouse immunoglobulins.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Polyclonal
<b>Host Species</b>	Goat
<b>Formulation</b>	Aqueous buffered solution containing a carrier protein and preservatives.
<b>Preparation</b>	The polyclonal antibody was purified from goat antiserum by mouse immunoglobulin affinity chromatography.
<b>Concentration</b>	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	<p>The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b></p> <p>To obtain lot-specific expiration date, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)</p> <p>This product has a shelf-life of 12 months or less. Please use our <a href="#">Expiration Lookup Tool</a> to verify the expiration date of your lot of product</p>
<b>Application</b>	<a href="#">ELISA - Quality tested</a> <a href="#">WB, IHC - Reported in the literature, not verified in house</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">ELISA assay</a> . <b>Do not use this product beyond the expiration date.</b> For ELISA or Western blot analysis, the reagent should be titrated between 1:2,000 - 1:5,000 to determine optimal conditions. For IHC on tissue sections, the reagent should be titrated between 1:500 - 1:2000 to determine optimal conditions. It is recommended that the reagent be titrated for optimal performance for each application. <b>Avoid using diluent solutions containing sodium azide. Sodium azide is an inhibitor of horseradish peroxidase.</b>
<b>Application Notes</b>	This polyclonal goat anti-mouse IgG antibody is useful for capture or detection of mouse IgG in ELISA.
<b>Application References</b>	
<b>(PubMed link indicates BioLegend citation)</b>	<ol style="list-style-type: none"><li>1. Scotta C, <i>et al.</i> 2008. <i>J Immunol.</i> 181:1025-33. <a href="#">PubMed</a></li><li>2. Gao X, <i>et al.</i> 2014. <i>Cell Mol Neurobiol.</i> 34:257-68 (<b>ICC</b>)</li><li>3. Winters T, <i>et al.</i> 2014. <i>EMBO J.</i> 33:1256-70.</li></ol>
<b>Product Citations</b>	<ol style="list-style-type: none"><li>1. Ma Y, <i>et al.</i> 2021. <i>Sci Rep.</i> 11:13471. <a href="#">PubMed</a></li><li>2. Rutkauskaitė J, <i>et al.</i> 2022. <i>iScience.</i> 25:104515. <a href="#">PubMed</a></li><li>3. Song E, <i>et al.</i> 2020. <i>bioRxiv.</i> . <a href="#">PubMed</a></li><li>4. Frank N, <i>et al.</i> 2011. <i>Cancer Res.</i> 71:1474. <a href="#">PubMed</a></li><li>5. Chen G, <i>et al.</i> 2018. <i>Front Immunol.</i> 9:549. <a href="#">PubMed</a></li><li>6. Israelow B, <i>et al.</i> 2020. <i>bioRxiv.</i> . <a href="#">PubMed</a></li><li>7. Uka R, <i>et al.</i> 2020. <i>Oncogene.</i> 39:4132. <a href="#">PubMed</a></li></ol>

8. Vrieling M, *et al.* 2016. *Sci Rep.* 6:37759. [PubMed](#)
9. Hwang S, *et al.* 2012. *Proc Natl Acad Sci U S A.* 110:276. [PubMed](#)
10. Boyt DT, *et al.* 2020. *J R Soc Interface.* 17:20190815. [PubMed](#)
11. Lin YR, *et al.* 2020. *Immunity.* 53(4):840-851.e6. [PubMed](#)
12. Biering SB *et al.* 2017. *Cell host & microbe.* 22(1):74-85. [PubMed](#)
13. de Mingo Pulido, *et al.* 2021. *Immunity.* 54(6):1154-1167.e7. [PubMed](#)
14. Gupta A, *et al.* 2020. *J Biol Chem.* 295:2057. [PubMed](#)
15. Copp J, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:13481. [PubMed](#)
16. Baba T, *et al.* 2021. *Cell Death Dis.* 12:322. [PubMed](#)
17. Chiang CF, *et al.* 2019. *Sci Rep.* 9:12448. [PubMed](#)
18. Parks KR, *et al.* 2019. *Cell Rep.* 29:3060. [PubMed](#)
19. Zhang S, *et al.* 2021. *Front Oncol.* 585457:11. [PubMed](#)
20. Nitiss JL, *et al.* 2021. *Curr Protoc.* 1:e250. [PubMed](#)
21. Martinov T, *et al.* 2019. *J Immunol.* 203:844. [PubMed](#)
22. Sharma A, *et al.* 2021. *Traffic.* .: [PubMed](#)
23. Yaguchi J, *et al.* 2021. *BMC Biology.* 19(1):64. [PubMed](#)
24. Ventura E, *et al.* 2018. *J Cell Sci.* 131. [PubMed](#)
25. Collin R, *et al.* 2014. *J Immunol.* 193:3503. [PubMed](#)
26. Song E, *et al.* 2021. *J Exp Med.* 218:00:00. [PubMed](#)
27. Nishigami Y, *et al.* 2016. *Sci Rep.* 6:18964. [PubMed](#)
28. Omer S *et al.* 2018. *eLife.* 7 pii: e36745. [PubMed](#)
29. Schadt L, *et al.* 2020. *Cell Reports.* 29(5):1236-1248.e7.. [PubMed](#)
30. Hoffmann D, *et al.* 2020. *Cancer Immunol Res.* 8:19. [PubMed](#)
31. Pibuel MA, *et al.* 2021. *Cell Death Discov.* 7:280. [PubMed](#)
32. Liu H, *et al.* 2020. *Cell Death Dis.* 0.767361111. [PubMed](#)
33. Furlong K, *et al.* 2020. *J Virol.* 94:00:00. [PubMed](#)
34. Yan L, *et al.* 2014. *Clin Vaccine Immunol.* 21:1206. [PubMed](#)
35. Mamedov T, *et al.* 2021. *Front Plant Sci.* 12:742875. [PubMed](#)
36. Fang Z, *et al.* 2022. *Nat Commun.* 13:3250. [PubMed](#)
37. Song E, *et al.* 2021. *Cell Rep Med.* 2:100288. [PubMed](#)
38. Lee K, *et al.* 2020. *Biology (Basel).* 9:00. [PubMed](#)
39. Powell AE, *et al.* 2020. *bioRxiv.* . [PubMed](#)
40. Powell AE, *et al.* 2022. *Front Immunol.* 13:942897. [PubMed](#)
41. Wang K, *et al.* 2021. *EMBO Rep.* 22:e52205. [PubMed](#)
42. Gopinath A, *et al.* 2022. *NPJ Parkinsons Dis.* 8:72. [PubMed](#)
43. Ohtsuka J, *et al.* 2021. *iScience.* Online ahead of print. [PubMed](#)
44. Harbour JC, *et al.* 2021. *J Immunol.* 206:2596. [PubMed](#)
45. Gopinath A, *et al.* 2021. *NPJ Parkinsons Dis.* 7:62. [PubMed](#)
46. Seydoux E, *et al.* 2021. *Cell Reports.* 35(5):109084. [PubMed](#)
47. Caglar Beker M, *et al.* 2020. *Turk J Med Sci.* Online ahead of print. [PubMed](#)
48. Hsing C, *et al.* 2008. *Cytokine.* 44:221. [PubMed](#)
49. Sertorio M, *et al.* 2016. *J Immunol.* 196: 2986-2994. [PubMed](#)
50. Hsu HW, *et al.* 2020. *Development.* 147:00:00. [PubMed](#)
51. Khan AA, *et al.* 2022. *Bioconjug Chem.* . [PubMed](#)
52. Wang C, *et al.* 2019. *PLoS Pathog.* 15:e1007938. [PubMed](#)
53. Ram AK, *et al.* 2020. *World J Gastroenterol.* 26:7131. [PubMed](#)
54. Zhang Q, *et al.* 2021. *Front Cell Infect Microbiol.* 11:766922. [PubMed](#)
55. Lee SH, *et al.* 2022. *Nat Commun.* 13:5461. [PubMed](#)
56. Chung KP, *et al.* 2019. *Nat Commun.* 10:3390. [PubMed](#)
57. Jin SW, *et al.* 2019. *Cell Rep.* 29:1449. [PubMed](#)
58. Shkoporov A, *et al.* 2015. *FEMS Microbiol Lett.* 362:83. [PubMed](#)
59. Christin JR, *et al.* 2020. *Cell Reports.* 31(10):107742. [PubMed](#)
60. Viereckl MJ, *et al.* 2022. *Biomolecules.* 12:. [PubMed](#)
61. Klaessens S, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118:. [PubMed](#)
62. Kiianitsa K, *et al.* 2020. *DNA Repair (Amst).* 96:102977. [PubMed](#)
63. Israelow B, *et al.* 2020. *J Exp Med.* 217:00:00. [PubMed](#)
64. Powell AE, *et al.* 2021. *ACS Cent Sci.* 7:183. [PubMed](#)
65. Tao L, *et al.* 2021. *Light Sci Appl.* 10:179. [PubMed](#)
66. Prakash P, *et al.* 2019. *Methods Protoc.* 2:48. [PubMed](#)
67. Wu YH, *et al.* 2020. *Mol Med Rep.* 21:851. [PubMed](#)
68. Horton N, *et al.* 2013. *PLoS One.* 8:e59552. [PubMed](#)
69. Nanna AR, *et al.* 2020. *Nucleic Acids Res.* 48:5281. [PubMed](#)
70. Liang YH, *et al.* 2021. *J Biomed Sci.* 28:75. [PubMed](#)
71. Lun Y, *et al.* 2021. *J Immunol.* 206:2819. [PubMed](#)
72. Rodems TS, *et al.* 2022. *Commun Biol.* 5:897. [PubMed](#)
73. Ortega-Prieto AM, *et al.* 2018. *Nat Commun.* 9:682. [PubMed](#)
74. Han G, *et al.* 2022. *Ann Transl Med.* 10:1134. [PubMed](#)
75. Harbuzariu A, *et al.* 2022. *iScience.* 25:104407. [PubMed](#)
76. Huang WC, *et al.* 2022. *Sci Rep.* 12:3612. [PubMed](#)
77. Hoffmann D, *et al.* 2020. *Int J Tryptophan Res.* 12:1178646919891736. [PubMed](#)
78. Zhang B, *et al.* 2020. *J Exp Med.* 217:e20182365. [PubMed](#)
79. Miyamoto M, *et al.* 2018. *Oncol Lett.* 15:4005. [PubMed](#)
80. Spanier J, *et al.* 2016. *Nat Commun.* 7:11804. [PubMed](#)

## Antigen Details

---

<b>Distribution</b>	B cells
<b>Gene ID</b>	<a href="#">16059</a>

## Related Protocols

---

[Sandwich ELISA Protocol](#)

## Other Formats

---

APC Goat anti-mouse IgG (minimal x-reactivity), Biotin Goat anti-mouse IgG (minimal x-reactivity), FITC Goat anti-mouse IgG (minimal x-reactivity), HRP Goat anti-mouse IgG (minimal x-reactivity), PE Goat anti-mouse IgG (minimal x-reactivity), Purified Goat anti-mouse IgG (minimal x-reactivity), Cyanine3 Goat anti-mouse IgG (minimal x-reactivity), PE/Cyanine7 Goat anti-mouse IgG (minimal x-reactivity), PerCP/Cyanine5.5 Goat anti-mouse IgG (minimal x-reactivity), DyLight™ 488 Goat anti-mouse IgG (minimal x-reactivity), DyLight™ 649 Goat anti-mouse IgG (minimal x-reactivity), Alexa Fluor® 594 Goat anti-mouse IgG (minimal x-reactivity), APC/Cyanine7 Goat anti-mouse IgG (minimal x-reactivity), Brilliant Violet 421™ Goat anti-mouse IgG (minimal x-reactivity), Alexa Fluor® 488 Goat anti-mouse IgG (minimal x-reactivity), Alexa Fluor® 647 Goat anti-mouse IgG (minimal x-reactivity), Alexa Fluor® 555 Goat anti-mouse IgG (minimal x-reactivity), Brilliant Violet 605™ Goat anti-mouse IgG (minimal x-reactivity), Brilliant Violet 510™ Goat anti-mouse IgG (minimal x-reactivity), PE/Dazzle™ 594 Goat anti-mouse IgG (minimal x-reactivity), PerCP Goat anti-mouse IgG (minimal x-reactivity), APC/Fire™ 750 Goat anti-mouse IgG (minimal x-reactivity), Spark YG™ 570 Goat anti-mouse IgG (minimal x-reactivity)

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587